Search
Grail Inc
GRALAdd to Watchlist
65.870USD
-0.700-1.05%
Market hours （ET）Quotes delayed by 15 min
2.71BMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
-1.05%
5 Days
+3.34%
1 Month
-1.96%
6 Months
-28.29%
Year to Date
-23.04%
1 Year
+42.65%
Key Figures
65.560Open
67.460High
166.21KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.40%Turnover Ratio
66.570Prev. Close
65.050Low
7.88MTurnover
LossP/E Static
1.08P/B
0.00%Div Yield TTM
-13.99%ROA
118.84052wk High
0.40Volume Ratio
-2.03BNet Profit
41.13MShares
-10.3076EPS TTM
--Beta
-16.09%ROE
29.95052wk Low
3.62%Amplitude
-35.08%Gross Margin
2.71BMarket Cap
-1.43Reward/Risk
4.74%Risk Rate
TradingKey Stock Score of Grail Inc
Currency: USD Updated: 2026-06-25Key Insights
Grail Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 71 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 64.27.In the medium term, the stock price is expected to trend up.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Grail Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Grail Inc Highlights
StrengthsRisks
Grail, Inc. is a healthcare company focused on saving lives and shifting the paradigm in early cancer detection. The Company is focused on alleviating the global burden of cancer by using sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its multi-cancer early detection test, the Galleri test, is a commercially available screening test for early detection of multiple types of cancer. The Galleri test can be used to screen for cancer before a person becomes symptomatic, when cancer may be more easily treated and potentially curable. The Galleri test can indicate the origin of the cancer.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 58.07% year-on-year.
Undervalued
The company’s latest PE is -6.46, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 33.74M shares, increasing 4.97% quarter-over-quarter.
Held by Paul Tudor Jones
Star Investor Paul Tudor Jones holds 22.82K shares of this stock.
Analyst Rating
Based on
9
analysts
Buy
Current Rating
64.266
Target Price
+5.16%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Grail Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Grail Inc Info
Grail, Inc. is a healthcare company focused on saving lives and shifting the paradigm in early cancer detection. The Company is focused on alleviating the global burden of cancer by using sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its multi-cancer early detection test, the Galleri test, is a commercially available screening test for early detection of multiple types of cancer. The Galleri test can be used to screen for cancer before a person becomes symptomatic, when cancer may be more easily treated and potentially curable. The Galleri test can indicate the origin of the cancer.
Ticker SymbolGRAL
CompanyGrail Inc
CEORagusa (Robert)
Websitehttps://grail.com/
Related Instruments
+6.49%
+3.63%
+2.00%
+1.41%
+1.95%
+0.36%
+1.28%
+0.72%
+1.95%
+1.92%
+2.61%
+2.97%
+0.74%
+1.87%
+0.89%
0.00%
+1.84%
+1.61%
-0.25%
+1.34%Popular Instruments
51940.100
-84.600 (-0.16%)
29290.800
-164.200 (-0.56%)
7367.600
+0.800 (+0.01%)
15286.000
-465.000 (-2.95%)
69797.000
-1335.000 (-1.88%)
6219.700
-46.100 (-0.74%)
69.158
-2.186 (-3.06%)
279.260
+4.110 (+1.49%)
194.590
-1.150 (-0.59%)
4082.420
+56.270 (+1.40%)
FAQs
What is the current price of Grail Inc (GRAL)?
The current price of Grail Inc (GRAL) is 66.57.
What is the symbol of Grail Inc?
The ticker symbol of Grail Inc is GRAL.
What is the 52-week high of Grail Inc?
The 52-week high of Grail Inc is 118.84.
What is the 52-week low of Grail Inc?
The 52-week low of Grail Inc is 29.95.
What is the market capitalization of Grail Inc?
The market capitalization of Grail Inc is 2.86B.
Is Grail Inc (GRAL) currently rated as Buy, Hold, or Sell?
According to analysts, Grail Inc (GRAL) has an overall rating of Buy, with a price target of 64.27.
What is the Earnings Per Share (EPS TTM) of Grail Inc (GRAL)?
The Earnings Per Share (EPS TTM) of Grail Inc (GRAL) is -11.11.
